nodes	percent_of_prediction	percent_of_DWPC	metapath
Trametinib—CYP2C8—Amprenavir—acquired immunodeficiency syndrome	0.0736	0.125	CbGbCtD
Trametinib—CYP2C8—Delavirdine—acquired immunodeficiency syndrome	0.0736	0.125	CbGbCtD
Trametinib—CYP2C8—Ritonavir—acquired immunodeficiency syndrome	0.0558	0.0944	CbGbCtD
Trametinib—CYP2C8—Saquinavir—acquired immunodeficiency syndrome	0.0558	0.0944	CbGbCtD
Trametinib—CYP2C8—Zidovudine—acquired immunodeficiency syndrome	0.0535	0.0905	CbGbCtD
Trametinib—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.0351	0.0594	CbGbCtD
Trametinib—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.033	0.0559	CbGbCtD
Trametinib—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.033	0.0559	CbGbCtD
Trametinib—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.0299	0.0505	CbGbCtD
Trametinib—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.0299	0.0505	CbGbCtD
Trametinib—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.0258	0.0436	CbGbCtD
Trametinib—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.025	0.0423	CbGbCtD
Trametinib—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.0226	0.0383	CbGbCtD
Trametinib—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.0226	0.0383	CbGbCtD
Trametinib—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.0217	0.0367	CbGbCtD
Trametinib—MAP2K2—blood plasma—acquired immunodeficiency syndrome	0.00679	0.0992	CbGeAlD
Trametinib—MAP2K1—skin of body—acquired immunodeficiency syndrome	0.00371	0.0542	CbGeAlD
Trametinib—MAP2K2—skin of body—acquired immunodeficiency syndrome	0.00326	0.0477	CbGeAlD
Trametinib—MAP2K1—lymphoid tissue—acquired immunodeficiency syndrome	0.003	0.0439	CbGeAlD
Trametinib—MAP2K1—digestive system—acquired immunodeficiency syndrome	0.00297	0.0433	CbGeAlD
Trametinib—MAP2K1—blood—acquired immunodeficiency syndrome	0.00283	0.0413	CbGeAlD
Trametinib—MAP2K1—bone marrow—acquired immunodeficiency syndrome	0.00273	0.04	CbGeAlD
Trametinib—MAP2K1—spinal cord—acquired immunodeficiency syndrome	0.00272	0.0398	CbGeAlD
Trametinib—MAP2K2—lymphoid tissue—acquired immunodeficiency syndrome	0.00264	0.0386	CbGeAlD
Trametinib—MAP2K2—digestive system—acquired immunodeficiency syndrome	0.00261	0.0382	CbGeAlD
Trametinib—MAP2K2—blood—acquired immunodeficiency syndrome	0.00249	0.0364	CbGeAlD
Trametinib—MAP2K1—lung—acquired immunodeficiency syndrome	0.00248	0.0362	CbGeAlD
Trametinib—MAP2K2—bone marrow—acquired immunodeficiency syndrome	0.00241	0.0352	CbGeAlD
Trametinib—MAP2K2—spinal cord—acquired immunodeficiency syndrome	0.0024	0.035	CbGeAlD
Trametinib—CYP2C8—blood plasma—acquired immunodeficiency syndrome	0.00235	0.0344	CbGeAlD
Trametinib—MAP2K1—nervous system—acquired immunodeficiency syndrome	0.00229	0.0335	CbGeAlD
Trametinib—MAP2K1—central nervous system—acquired immunodeficiency syndrome	0.00221	0.0323	CbGeAlD
Trametinib—MAP2K2—lung—acquired immunodeficiency syndrome	0.00218	0.0319	CbGeAlD
Trametinib—MAP2K2—nervous system—acquired immunodeficiency syndrome	0.00202	0.0295	CbGeAlD
Trametinib—MAP2K2—central nervous system—acquired immunodeficiency syndrome	0.00194	0.0284	CbGeAlD
Trametinib—MAP2K1—brain—acquired immunodeficiency syndrome	0.00175	0.0256	CbGeAlD
Trametinib—MAP2K1—lymph node—acquired immunodeficiency syndrome	0.00169	0.0248	CbGeAlD
Trametinib—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.00159	0.0233	CbGeAlD
Trametinib—MAP2K2—brain—acquired immunodeficiency syndrome	0.00154	0.0226	CbGeAlD
Trametinib—MAP2K2—lymph node—acquired immunodeficiency syndrome	0.00149	0.0218	CbGeAlD
Trametinib—CYP2C8—blood—acquired immunodeficiency syndrome	0.000861	0.0126	CbGeAlD
Trametinib—CYP2C8—vagina—acquired immunodeficiency syndrome	0.000798	0.0117	CbGeAlD
Trametinib—CYP3A4—digestive system—acquired immunodeficiency syndrome	0.000612	0.00895	CbGeAlD
Trametinib—CYP3A4—blood—acquired immunodeficiency syndrome	0.000583	0.00853	CbGeAlD
Trametinib—CYP2C8—brain—acquired immunodeficiency syndrome	0.000534	0.00781	CbGeAlD
Trametinib—CYP3A4—nervous system—acquired immunodeficiency syndrome	0.000474	0.00692	CbGeAlD
Trametinib—CYP3A4—central nervous system—acquired immunodeficiency syndrome	0.000456	0.00667	CbGeAlD
Trametinib—MAP2K1—Signalling to RAS—IL6—acquired immunodeficiency syndrome	0.000278	0.00374	CbGpPWpGaD
Trametinib—MAP2K1—VEGFR2 mediated cell proliferation—IL6—acquired immunodeficiency syndrome	0.000278	0.00374	CbGpPWpGaD
Trametinib—MAP2K1—Aryl Hydrocarbon Receptor—TNF—acquired immunodeficiency syndrome	0.00027	0.00364	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000265	0.00357	CbGpPWpGaD
Trametinib—MAP2K1—Ceramide signaling pathway—TNF—acquired immunodeficiency syndrome	0.000261	0.00352	CbGpPWpGaD
Trametinib—MAP2K2—TCR Signaling Pathway—CD4—acquired immunodeficiency syndrome	0.000252	0.00339	CbGpPWpGaD
Trametinib—MAP2K2—Cardiac Hypertrophic Response—TNF—acquired immunodeficiency syndrome	0.00025	0.00337	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000248	0.00334	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—ACTG1—acquired immunodeficiency syndrome	0.000247	0.00333	CbGpPWpGaD
Trametinib—MAP2K2—IL-6 signaling pathway—IL6—acquired immunodeficiency syndrome	0.000246	0.00331	CbGpPWpGaD
Trametinib—MAP2K2—FCERI mediated MAPK activation—IL6—acquired immunodeficiency syndrome	0.000246	0.00331	CbGpPWpGaD
Trametinib—MAP2K2—DAP12 interactions—HLA-B—acquired immunodeficiency syndrome	0.000246	0.00331	CbGpPWpGaD
Trametinib—MAP2K2—Signalling to ERKs—IL6—acquired immunodeficiency syndrome	0.000241	0.00325	CbGpPWpGaD
Trametinib—MAP2K2—FRS2-mediated cascade—IL6—acquired immunodeficiency syndrome	0.000241	0.00325	CbGpPWpGaD
Trametinib—MAP2K1—TCR Signaling Pathway—CD4—acquired immunodeficiency syndrome	0.000236	0.00317	CbGpPWpGaD
Trametinib—Arthralgia—Efavirenz—acquired immunodeficiency syndrome	0.000234	0.00088	CcSEcCtD
Trametinib—Rash—Amprenavir—acquired immunodeficiency syndrome	0.000234	0.00088	CcSEcCtD
Trametinib—MAP2K1—Cardiac Hypertrophic Response—TNF—acquired immunodeficiency syndrome	0.000234	0.00315	CbGpPWpGaD
Trametinib—Muscle spasms—Ritonavir—acquired immunodeficiency syndrome	0.000234	0.000879	CcSEcCtD
Trametinib—Dermatitis—Amprenavir—acquired immunodeficiency syndrome	0.000234	0.000879	CcSEcCtD
Trametinib—Body temperature increased—Nelfinavir—acquired immunodeficiency syndrome	0.000233	0.000876	CcSEcCtD
Trametinib—Abdominal pain—Nelfinavir—acquired immunodeficiency syndrome	0.000233	0.000876	CcSEcCtD
Trametinib—Nervous system disorder—Indinavir—acquired immunodeficiency syndrome	0.000233	0.000875	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Zidovudine—acquired immunodeficiency syndrome	0.000233	0.000875	CcSEcCtD
Trametinib—Headache—Amprenavir—acquired immunodeficiency syndrome	0.000233	0.000874	CcSEcCtD
Trametinib—Thrombocytopenia—Indinavir—acquired immunodeficiency syndrome	0.000233	0.000874	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Efavirenz—acquired immunodeficiency syndrome	0.000233	0.000874	CcSEcCtD
Trametinib—Body temperature increased—Stavudine—acquired immunodeficiency syndrome	0.000233	0.000873	CcSEcCtD
Trametinib—Abdominal pain—Stavudine—acquired immunodeficiency syndrome	0.000233	0.000873	CcSEcCtD
Trametinib—Diarrhoea—Didanosine—acquired immunodeficiency syndrome	0.000232	0.00087	CcSEcCtD
Trametinib—Mediastinal disorder—Lamivudine—acquired immunodeficiency syndrome	0.000232	0.000869	CcSEcCtD
Trametinib—MAP2K1—Developmental Biology—ACTG1—acquired immunodeficiency syndrome	0.000231	0.00312	CbGpPWpGaD
Trametinib—Insomnia—Zidovudine—acquired immunodeficiency syndrome	0.000231	0.000868	CcSEcCtD
Trametinib—Skin disorder—Indinavir—acquired immunodeficiency syndrome	0.000231	0.000867	CcSEcCtD
Trametinib—Chills—Lamivudine—acquired immunodeficiency syndrome	0.000231	0.000865	CcSEcCtD
Trametinib—MAP2K1—IL-6 signaling pathway—IL6—acquired immunodeficiency syndrome	0.00023	0.0031	CbGpPWpGaD
Trametinib—MAP2K1—FCERI mediated MAPK activation—IL6—acquired immunodeficiency syndrome	0.00023	0.0031	CbGpPWpGaD
Trametinib—Hyperhidrosis—Indinavir—acquired immunodeficiency syndrome	0.00023	0.000863	CcSEcCtD
Trametinib—Cough—Delavirdine—acquired immunodeficiency syndrome	0.00023	0.000863	CcSEcCtD
Trametinib—MAP2K1—DAP12 interactions—HLA-B—acquired immunodeficiency syndrome	0.00023	0.00309	CbGpPWpGaD
Trametinib—Dysgeusia—Saquinavir—acquired immunodeficiency syndrome	0.00023	0.000862	CcSEcCtD
Trametinib—Vision blurred—Ritonavir—acquired immunodeficiency syndrome	0.00023	0.000862	CcSEcCtD
Trametinib—Dry mouth—Efavirenz—acquired immunodeficiency syndrome	0.000229	0.000861	CcSEcCtD
Trametinib—Abdominal pain—Abacavir—acquired immunodeficiency syndrome	0.000229	0.00086	CcSEcCtD
Trametinib—Body temperature increased—Abacavir—acquired immunodeficiency syndrome	0.000229	0.00086	CcSEcCtD
Trametinib—MAP2K2—Interleukin-2 signaling—IL6—acquired immunodeficiency syndrome	0.000229	0.00308	CbGpPWpGaD
Trametinib—MAP2K2—TSLP Signaling Pathway—IL6—acquired immunodeficiency syndrome	0.000229	0.00308	CbGpPWpGaD
Trametinib—Hypertension—Delavirdine—acquired immunodeficiency syndrome	0.000227	0.000854	CcSEcCtD
Trametinib—Back pain—Saquinavir—acquired immunodeficiency syndrome	0.000227	0.000851	CcSEcCtD
Trametinib—MAP2K2—Cytokine Signaling in Immune system—IFNA1—acquired immunodeficiency syndrome	0.000226	0.00304	CbGpPWpGaD
Trametinib—MAP2K1—Signalling to ERKs—IL6—acquired immunodeficiency syndrome	0.000226	0.00304	CbGpPWpGaD
Trametinib—MAP2K1—FRS2-mediated cascade—IL6—acquired immunodeficiency syndrome	0.000226	0.00304	CbGpPWpGaD
Trametinib—Muscle spasms—Saquinavir—acquired immunodeficiency syndrome	0.000225	0.000846	CcSEcCtD
Trametinib—Anaemia—Ritonavir—acquired immunodeficiency syndrome	0.000225	0.000845	CcSEcCtD
Trametinib—Arthralgia—Delavirdine—acquired immunodeficiency syndrome	0.000224	0.000842	CcSEcCtD
Trametinib—Myalgia—Delavirdine—acquired immunodeficiency syndrome	0.000224	0.000842	CcSEcCtD
Trametinib—Malnutrition—Lamivudine—acquired immunodeficiency syndrome	0.000224	0.00084	CcSEcCtD
Trametinib—Erythema—Lamivudine—acquired immunodeficiency syndrome	0.000224	0.00084	CcSEcCtD
Trametinib—Decreased appetite—Zidovudine—acquired immunodeficiency syndrome	0.000222	0.000834	CcSEcCtD
Trametinib—Nausea—Amprenavir—acquired immunodeficiency syndrome	0.000221	0.000829	CcSEcCtD
Trametinib—Gastrointestinal disorder—Zidovudine—acquired immunodeficiency syndrome	0.000221	0.000829	CcSEcCtD
Trametinib—Fatigue—Zidovudine—acquired immunodeficiency syndrome	0.00022	0.000828	CcSEcCtD
Trametinib—Nervous system disorder—Efavirenz—acquired immunodeficiency syndrome	0.00022	0.000827	CcSEcCtD
Trametinib—Thrombocytopenia—Efavirenz—acquired immunodeficiency syndrome	0.00022	0.000826	CcSEcCtD
Trametinib—Dry mouth—Delavirdine—acquired immunodeficiency syndrome	0.000219	0.000823	CcSEcCtD
Trametinib—Dysgeusia—Lamivudine—acquired immunodeficiency syndrome	0.000219	0.000822	CcSEcCtD
Trametinib—Constipation—Zidovudine—acquired immunodeficiency syndrome	0.000219	0.000821	CcSEcCtD
Trametinib—Asthenia—Nevirapine—acquired immunodeficiency syndrome	0.000219	0.000821	CcSEcCtD
Trametinib—MAP2K2—Innate Immune System—ACTG1—acquired immunodeficiency syndrome	0.000218	0.00294	CbGpPWpGaD
Trametinib—Skin disorder—Efavirenz—acquired immunodeficiency syndrome	0.000218	0.000819	CcSEcCtD
Trametinib—Leukopenia—Ritonavir—acquired immunodeficiency syndrome	0.000218	0.000819	CcSEcCtD
Trametinib—Hyperhidrosis—Efavirenz—acquired immunodeficiency syndrome	0.000217	0.000815	CcSEcCtD
Trametinib—Anaemia—Saquinavir—acquired immunodeficiency syndrome	0.000217	0.000813	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Indinavir—acquired immunodeficiency syndrome	0.000217	0.000813	CcSEcCtD
Trametinib—MAP2K2—Downstream signaling in naïve CD8+ T cells—TNF—acquired immunodeficiency syndrome	0.000216	0.00291	CbGpPWpGaD
Trametinib—Back pain—Lamivudine—acquired immunodeficiency syndrome	0.000216	0.000812	CcSEcCtD
Trametinib—MAP2K1—Senescence and Autophagy in Cancer—IFNG—acquired immunodeficiency syndrome	0.000216	0.0029	CbGpPWpGaD
Trametinib—Pruritus—Nevirapine—acquired immunodeficiency syndrome	0.000216	0.000809	CcSEcCtD
Trametinib—Vomiting—Didanosine—acquired immunodeficiency syndrome	0.000215	0.000809	CcSEcCtD
Trametinib—Insomnia—Indinavir—acquired immunodeficiency syndrome	0.000215	0.000807	CcSEcCtD
Trametinib—Muscle spasms—Lamivudine—acquired immunodeficiency syndrome	0.000215	0.000807	CcSEcCtD
Trametinib—Oedema—Delavirdine—acquired immunodeficiency syndrome	0.000215	0.000807	CcSEcCtD
Trametinib—MAP2K1—Interleukin-2 signaling—IL6—acquired immunodeficiency syndrome	0.000214	0.00289	CbGpPWpGaD
Trametinib—MAP2K1—TSLP Signaling Pathway—IL6—acquired immunodeficiency syndrome	0.000214	0.00289	CbGpPWpGaD
Trametinib—Rash—Didanosine—acquired immunodeficiency syndrome	0.000214	0.000802	CcSEcCtD
Trametinib—Infection—Delavirdine—acquired immunodeficiency syndrome	0.000214	0.000802	CcSEcCtD
Trametinib—Dermatitis—Didanosine—acquired immunodeficiency syndrome	0.000213	0.000801	CcSEcCtD
Trametinib—MAP2K1—Corticotropin-releasing hormone—IL2—acquired immunodeficiency syndrome	0.000213	0.00287	CbGpPWpGaD
Trametinib—Cough—Ritonavir—acquired immunodeficiency syndrome	0.000213	0.000798	CcSEcCtD
Trametinib—Headache—Didanosine—acquired immunodeficiency syndrome	0.000212	0.000797	CcSEcCtD
Trametinib—Asthenia—Nelfinavir—acquired immunodeficiency syndrome	0.000212	0.000795	CcSEcCtD
Trametinib—MAP2K1—Cytokine Signaling in Immune system—IFNA1—acquired immunodeficiency syndrome	0.000211	0.00285	CbGpPWpGaD
Trametinib—Asthenia—Stavudine—acquired immunodeficiency syndrome	0.000211	0.000792	CcSEcCtD
Trametinib—Thrombocytopenia—Delavirdine—acquired immunodeficiency syndrome	0.00021	0.00079	CcSEcCtD
Trametinib—Hypertension—Ritonavir—acquired immunodeficiency syndrome	0.00021	0.000789	CcSEcCtD
Trametinib—Leukopenia—Saquinavir—acquired immunodeficiency syndrome	0.00021	0.000788	CcSEcCtD
Trametinib—Gastrointestinal pain—Zidovudine—acquired immunodeficiency syndrome	0.000209	0.000785	CcSEcCtD
Trametinib—Skin disorder—Delavirdine—acquired immunodeficiency syndrome	0.000209	0.000784	CcSEcCtD
Trametinib—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	0.000209	0.000784	CcSEcCtD
Trametinib—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	0.000208	0.000783	CcSEcCtD
Trametinib—Pruritus—Stavudine—acquired immunodeficiency syndrome	0.000208	0.000781	CcSEcCtD
Trametinib—Asthenia—Abacavir—acquired immunodeficiency syndrome	0.000208	0.000781	CcSEcCtD
Trametinib—Hyperhidrosis—Delavirdine—acquired immunodeficiency syndrome	0.000208	0.00078	CcSEcCtD
Trametinib—Arthralgia—Ritonavir—acquired immunodeficiency syndrome	0.000207	0.000779	CcSEcCtD
Trametinib—Myalgia—Ritonavir—acquired immunodeficiency syndrome	0.000207	0.000779	CcSEcCtD
Trametinib—Decreased appetite—Indinavir—acquired immunodeficiency syndrome	0.000207	0.000776	CcSEcCtD
Trametinib—Anaemia—Lamivudine—acquired immunodeficiency syndrome	0.000207	0.000776	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	0.000206	0.000773	CcSEcCtD
Trametinib—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	0.000205	0.000771	CcSEcCtD
Trametinib—Pruritus—Abacavir—acquired immunodeficiency syndrome	0.000205	0.00077	CcSEcCtD
Trametinib—Fatigue—Indinavir—acquired immunodeficiency syndrome	0.000205	0.00077	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	0.000205	0.000768	CcSEcCtD
Trametinib—Cough—Saquinavir—acquired immunodeficiency syndrome	0.000205	0.000768	CcSEcCtD
Trametinib—MAP2K1—Innate Immune System—ACTG1—acquired immunodeficiency syndrome	0.000204	0.00275	CbGpPWpGaD
Trametinib—Constipation—Indinavir—acquired immunodeficiency syndrome	0.000203	0.000763	CcSEcCtD
Trametinib—Insomnia—Efavirenz—acquired immunodeficiency syndrome	0.000203	0.000763	CcSEcCtD
Trametinib—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	0.000203	0.000761	CcSEcCtD
Trametinib—Hypertension—Saquinavir—acquired immunodeficiency syndrome	0.000202	0.00076	CcSEcCtD
Trametinib—MAP2K1—Downstream signaling in naïve CD8+ T cells—TNF—acquired immunodeficiency syndrome	0.000202	0.00273	CbGpPWpGaD
Trametinib—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	0.000202	0.000759	CcSEcCtD
Trametinib—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	0.000202	0.000759	CcSEcCtD
Trametinib—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	0.000202	0.000758	CcSEcCtD
Trametinib—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	0.000201	0.000756	CcSEcCtD
Trametinib—Nausea—Didanosine—acquired immunodeficiency syndrome	0.000201	0.000756	CcSEcCtD
Trametinib—MAP2K2—Signaling by Interleukins—IL2—acquired immunodeficiency syndrome	0.0002	0.0027	CbGpPWpGaD
Trametinib—Leukopenia—Lamivudine—acquired immunodeficiency syndrome	0.0002	0.000752	CcSEcCtD
Trametinib—Arthralgia—Saquinavir—acquired immunodeficiency syndrome	0.0002	0.000749	CcSEcCtD
Trametinib—Myalgia—Saquinavir—acquired immunodeficiency syndrome	0.0002	0.000749	CcSEcCtD
Trametinib—MAP2K2—MAP kinase activation in TLR cascade—IL6—acquired immunodeficiency syndrome	0.000199	0.00268	CbGpPWpGaD
Trametinib—Oedema—Ritonavir—acquired immunodeficiency syndrome	0.000199	0.000746	CcSEcCtD
Trametinib—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	0.000198	0.000744	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	0.000198	0.000744	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	0.000196	0.000735	CcSEcCtD
Trametinib—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	0.000195	0.000733	CcSEcCtD
Trametinib—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	0.000195	0.000733	CcSEcCtD
Trametinib—Cough—Lamivudine—acquired immunodeficiency syndrome	0.000195	0.000733	CcSEcCtD
Trametinib—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.000195	0.000733	CcSEcCtD
Trametinib—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	0.000195	0.000732	CcSEcCtD
Trametinib—Thrombocytopenia—Ritonavir—acquired immunodeficiency syndrome	0.000195	0.000731	CcSEcCtD
Trametinib—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.000195	0.00073	CcSEcCtD
Trametinib—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	0.000194	0.00073	CcSEcCtD
Trametinib—Insomnia—Delavirdine—acquired immunodeficiency syndrome	0.000194	0.00073	CcSEcCtD
Trametinib—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	0.000194	0.000728	CcSEcCtD
Trametinib—Vomiting—Nevirapine—acquired immunodeficiency syndrome	0.000194	0.000727	CcSEcCtD
Trametinib—Fatigue—Efavirenz—acquired immunodeficiency syndrome	0.000194	0.000727	CcSEcCtD
Trametinib—MAP2K2—SHP2 signaling—IL6—acquired immunodeficiency syndrome	0.000194	0.00261	CbGpPWpGaD
Trametinib—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	0.000193	0.000725	CcSEcCtD
Trametinib—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	0.000192	0.000721	CcSEcCtD
Trametinib—Constipation—Efavirenz—acquired immunodeficiency syndrome	0.000192	0.000721	CcSEcCtD
Trametinib—Rash—Nevirapine—acquired immunodeficiency syndrome	0.000192	0.000721	CcSEcCtD
Trametinib—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	0.000192	0.000721	CcSEcCtD
Trametinib—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.000192	0.000719	CcSEcCtD
Trametinib—Oedema—Saquinavir—acquired immunodeficiency syndrome	0.000191	0.000718	CcSEcCtD
Trametinib—Headache—Nevirapine—acquired immunodeficiency syndrome	0.000191	0.000717	CcSEcCtD
Trametinib—Myalgia—Lamivudine—acquired immunodeficiency syndrome	0.00019	0.000715	CcSEcCtD
Trametinib—Arthralgia—Lamivudine—acquired immunodeficiency syndrome	0.00019	0.000715	CcSEcCtD
Trametinib—Infection—Saquinavir—acquired immunodeficiency syndrome	0.00019	0.000714	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	0.000189	0.00071	CcSEcCtD
Trametinib—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	0.000188	0.000706	CcSEcCtD
Trametinib—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	0.000188	0.000706	CcSEcCtD
Trametinib—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	0.000188	0.000704	CcSEcCtD
Trametinib—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	0.000188	0.000704	CcSEcCtD
Trametinib—MAP2K1—Signaling by Interleukins—IL2—acquired immunodeficiency syndrome	0.000187	0.00252	CbGpPWpGaD
Trametinib—Thrombocytopenia—Saquinavir—acquired immunodeficiency syndrome	0.000187	0.000703	CcSEcCtD
Trametinib—Vomiting—Stavudine—acquired immunodeficiency syndrome	0.000187	0.000702	CcSEcCtD
Trametinib—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	0.000187	0.000702	CcSEcCtD
Trametinib—MAP2K1—MAP kinase activation in TLR cascade—IL6—acquired immunodeficiency syndrome	0.000186	0.00251	CbGpPWpGaD
Trametinib—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	0.000186	0.000699	CcSEcCtD
Trametinib—Rash—Nelfinavir—acquired immunodeficiency syndrome	0.000186	0.000699	CcSEcCtD
Trametinib—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	0.000186	0.000698	CcSEcCtD
Trametinib—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	0.000186	0.000698	CcSEcCtD
Trametinib—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	0.000186	0.000697	CcSEcCtD
Trametinib—Rash—Stavudine—acquired immunodeficiency syndrome	0.000185	0.000696	CcSEcCtD
Trametinib—Fatigue—Delavirdine—acquired immunodeficiency syndrome	0.000185	0.000696	CcSEcCtD
Trametinib—Dermatitis—Stavudine—acquired immunodeficiency syndrome	0.000185	0.000696	CcSEcCtD
Trametinib—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	0.000185	0.000694	CcSEcCtD
Trametinib—Headache—Nelfinavir—acquired immunodeficiency syndrome	0.000185	0.000694	CcSEcCtD
Trametinib—Headache—Stavudine—acquired immunodeficiency syndrome	0.000184	0.000692	CcSEcCtD
Trametinib—Vomiting—Abacavir—acquired immunodeficiency syndrome	0.000184	0.000692	CcSEcCtD
Trametinib—Constipation—Delavirdine—acquired immunodeficiency syndrome	0.000184	0.00069	CcSEcCtD
Trametinib—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	0.000184	0.00069	CcSEcCtD
Trametinib—Asthenia—Zidovudine—acquired immunodeficiency syndrome	0.000183	0.000689	CcSEcCtD
Trametinib—Rash—Abacavir—acquired immunodeficiency syndrome	0.000183	0.000686	CcSEcCtD
Trametinib—Dermatitis—Abacavir—acquired immunodeficiency syndrome	0.000183	0.000685	CcSEcCtD
Trametinib—Oedema—Lamivudine—acquired immunodeficiency syndrome	0.000183	0.000685	CcSEcCtD
Trametinib—Headache—Abacavir—acquired immunodeficiency syndrome	0.000182	0.000682	CcSEcCtD
Trametinib—Infection—Lamivudine—acquired immunodeficiency syndrome	0.000181	0.000681	CcSEcCtD
Trametinib—MAP2K1—SHP2 signaling—IL6—acquired immunodeficiency syndrome	0.000181	0.00244	CbGpPWpGaD
Trametinib—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	0.000181	0.00068	CcSEcCtD
Trametinib—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.000181	0.000679	CcSEcCtD
Trametinib—Pruritus—Zidovudine—acquired immunodeficiency syndrome	0.000181	0.000679	CcSEcCtD
Trametinib—Insomnia—Ritonavir—acquired immunodeficiency syndrome	0.00018	0.000675	CcSEcCtD
Trametinib—MAP2K2—Innate Immune System—MBL2—acquired immunodeficiency syndrome	0.00018	0.00242	CbGpPWpGaD
Trametinib—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	0.000179	0.000672	CcSEcCtD
Trametinib—Thrombocytopenia—Lamivudine—acquired immunodeficiency syndrome	0.000179	0.000671	CcSEcCtD
Trametinib—MAP2K2—MicroRNAs in cardiomyocyte hypertrophy—TNF—acquired immunodeficiency syndrome	0.000178	0.0024	CbGpPWpGaD
Trametinib—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	0.000178	0.000667	CcSEcCtD
Trametinib—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	0.000178	0.000667	CcSEcCtD
Trametinib—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	0.000177	0.000666	CcSEcCtD
Trametinib—MAP2K2—Cytokine Signaling in Immune system—CSF2—acquired immunodeficiency syndrome	0.000177	0.00238	CbGpPWpGaD
Trametinib—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	0.000176	0.000662	CcSEcCtD
Trametinib—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	0.000176	0.00066	CcSEcCtD
Trametinib—Nausea—Nelfinavir—acquired immunodeficiency syndrome	0.000175	0.000658	CcSEcCtD
Trametinib—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	0.000175	0.000657	CcSEcCtD
Trametinib—Nausea—Stavudine—acquired immunodeficiency syndrome	0.000175	0.000656	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	0.000174	0.000654	CcSEcCtD
Trametinib—Insomnia—Saquinavir—acquired immunodeficiency syndrome	0.000173	0.00065	CcSEcCtD
Trametinib—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	0.000173	0.000649	CcSEcCtD
Trametinib—Nausea—Abacavir—acquired immunodeficiency syndrome	0.000172	0.000646	CcSEcCtD
Trametinib—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	0.000172	0.000644	CcSEcCtD
Trametinib—Fatigue—Ritonavir—acquired immunodeficiency syndrome	0.000171	0.000643	CcSEcCtD
Trametinib—Asthenia—Indinavir—acquired immunodeficiency syndrome	0.000171	0.000641	CcSEcCtD
Trametinib—MAP2K2—NCAM signaling for neurite out-growth—IL6—acquired immunodeficiency syndrome	0.00017	0.0023	CbGpPWpGaD
Trametinib—MAP2K2—Cytokine Signaling in Immune system—HLA-B—acquired immunodeficiency syndrome	0.00017	0.00229	CbGpPWpGaD
Trametinib—Constipation—Ritonavir—acquired immunodeficiency syndrome	0.00017	0.000638	CcSEcCtD
Trametinib—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	0.00017	0.000638	CcSEcCtD
Trametinib—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	0.00017	0.000638	CcSEcCtD
Trametinib—Dizziness—Zidovudine—acquired immunodeficiency syndrome	0.000169	0.000635	CcSEcCtD
Trametinib—Pruritus—Indinavir—acquired immunodeficiency syndrome	0.000168	0.000632	CcSEcCtD
Trametinib—MAP2K1—Innate Immune System—MBL2—acquired immunodeficiency syndrome	0.000168	0.00226	CbGpPWpGaD
Trametinib—MAP2K1—MicroRNAs in cardiomyocyte hypertrophy—TNF—acquired immunodeficiency syndrome	0.000167	0.00225	CbGpPWpGaD
Trametinib—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	0.000166	0.000624	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	0.000166	0.000624	CcSEcCtD
Trametinib—MAP2K1—Cytokine Signaling in Immune system—CSF2—acquired immunodeficiency syndrome	0.000165	0.00223	CbGpPWpGaD
Trametinib—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	0.000165	0.00062	CcSEcCtD
Trametinib—Insomnia—Lamivudine—acquired immunodeficiency syndrome	0.000165	0.00062	CcSEcCtD
Trametinib—Fatigue—Saquinavir—acquired immunodeficiency syndrome	0.000165	0.000619	CcSEcCtD
Trametinib—Constipation—Saquinavir—acquired immunodeficiency syndrome	0.000164	0.000614	CcSEcCtD
Trametinib—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	0.000163	0.000611	CcSEcCtD
Trametinib—Vomiting—Zidovudine—acquired immunodeficiency syndrome	0.000163	0.00061	CcSEcCtD
Trametinib—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	0.000163	0.00061	CcSEcCtD
Trametinib—Rash—Zidovudine—acquired immunodeficiency syndrome	0.000161	0.000605	CcSEcCtD
Trametinib—Asthenia—Efavirenz—acquired immunodeficiency syndrome	0.000161	0.000605	CcSEcCtD
Trametinib—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	0.000161	0.000605	CcSEcCtD
Trametinib—MAP2K2—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000161	0.00216	CbGpPWpGaD
Trametinib—Headache—Zidovudine—acquired immunodeficiency syndrome	0.00016	0.000601	CcSEcCtD
Trametinib—MAP2K1—NCAM signaling for neurite out-growth—IL6—acquired immunodeficiency syndrome	0.000159	0.00215	CbGpPWpGaD
Trametinib—MAP2K2—Disease—APOBEC3G—acquired immunodeficiency syndrome	0.000159	0.00215	CbGpPWpGaD
Trametinib—MAP2K1—Cytokine Signaling in Immune system—HLA-B—acquired immunodeficiency syndrome	0.000159	0.00214	CbGpPWpGaD
Trametinib—Pruritus—Efavirenz—acquired immunodeficiency syndrome	0.000159	0.000597	CcSEcCtD
Trametinib—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	0.000159	0.000596	CcSEcCtD
Trametinib—MAP2K2—TRAF6 Mediated Induction of proinflammatory cytokines—IL6—acquired immunodeficiency syndrome	0.000158	0.00212	CbGpPWpGaD
Trametinib—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	0.000158	0.000592	CcSEcCtD
Trametinib—Fatigue—Lamivudine—acquired immunodeficiency syndrome	0.000157	0.000591	CcSEcCtD
Trametinib—Dizziness—Indinavir—acquired immunodeficiency syndrome	0.000157	0.00059	CcSEcCtD
Trametinib—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	0.000157	0.00059	CcSEcCtD
Trametinib—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	0.000157	0.00059	CcSEcCtD
Trametinib—MAP2K2—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000157	0.00211	CbGpPWpGaD
Trametinib—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	0.000156	0.000587	CcSEcCtD
Trametinib—Constipation—Lamivudine—acquired immunodeficiency syndrome	0.000156	0.000586	CcSEcCtD
Trametinib—Asthenia—Delavirdine—acquired immunodeficiency syndrome	0.000154	0.000579	CcSEcCtD
Trametinib—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	0.000154	0.000577	CcSEcCtD
Trametinib—MAP2K2—Toll-like Receptor Signaling Pathway—TNF—acquired immunodeficiency syndrome	0.000153	0.00206	CbGpPWpGaD
Trametinib—Pruritus—Delavirdine—acquired immunodeficiency syndrome	0.000152	0.000571	CcSEcCtD
Trametinib—Nausea—Zidovudine—acquired immunodeficiency syndrome	0.000152	0.00057	CcSEcCtD
Trametinib—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	0.000151	0.000568	CcSEcCtD
Trametinib—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	0.000151	0.000568	CcSEcCtD
Trametinib—Vomiting—Indinavir—acquired immunodeficiency syndrome	0.000151	0.000568	CcSEcCtD
Trametinib—MAP2K1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.00015	0.00202	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	0.00015	0.00202	CbGpPWpGaD
Trametinib—Rash—Indinavir—acquired immunodeficiency syndrome	0.00015	0.000563	CcSEcCtD
Trametinib—Dermatitis—Indinavir—acquired immunodeficiency syndrome	0.00015	0.000562	CcSEcCtD
Trametinib—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	0.000149	0.00056	CcSEcCtD
Trametinib—MAP2K1—Disease—APOBEC3G—acquired immunodeficiency syndrome	0.000149	0.00201	CbGpPWpGaD
Trametinib—Headache—Indinavir—acquired immunodeficiency syndrome	0.000149	0.000559	CcSEcCtD
Trametinib—Dizziness—Efavirenz—acquired immunodeficiency syndrome	0.000149	0.000558	CcSEcCtD
Trametinib—MAP2K1—TRAF6 Mediated Induction of proinflammatory cytokines—IL6—acquired immunodeficiency syndrome	0.000147	0.00199	CbGpPWpGaD
Trametinib—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	0.000147	0.000552	CcSEcCtD
Trametinib—MAP2K1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000147	0.00197	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000145	0.00196	CbGpPWpGaD
Trametinib—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	0.000144	0.000542	CcSEcCtD
Trametinib—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	0.000144	0.000542	CcSEcCtD
Trametinib—MAP2K1—Toll-like Receptor Signaling Pathway—TNF—acquired immunodeficiency syndrome	0.000143	0.00192	CbGpPWpGaD
Trametinib—Vomiting—Efavirenz—acquired immunodeficiency syndrome	0.000143	0.000536	CcSEcCtD
Trametinib—Asthenia—Ritonavir—acquired immunodeficiency syndrome	0.000143	0.000535	CcSEcCtD
Trametinib—MAP2K2—IRS-mediated signalling—IL6—acquired immunodeficiency syndrome	0.000143	0.00192	CbGpPWpGaD
Trametinib—MAP2K2—MyD88 cascade initiated on plasma membrane—IL6—acquired immunodeficiency syndrome	0.000143	0.00192	CbGpPWpGaD
Trametinib—Dizziness—Delavirdine—acquired immunodeficiency syndrome	0.000142	0.000534	CcSEcCtD
Trametinib—Rash—Efavirenz—acquired immunodeficiency syndrome	0.000142	0.000532	CcSEcCtD
Trametinib—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	0.000142	0.000531	CcSEcCtD
Trametinib—MAP2K2—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—IL6—acquired immunodeficiency syndrome	0.000141	0.0019	CbGpPWpGaD
Trametinib—Nausea—Indinavir—acquired immunodeficiency syndrome	0.000141	0.00053	CcSEcCtD
Trametinib—MAP2K2—Innate Immune System—CCR2—acquired immunodeficiency syndrome	0.000141	0.0019	CbGpPWpGaD
Trametinib—Headache—Efavirenz—acquired immunodeficiency syndrome	0.000141	0.000528	CcSEcCtD
Trametinib—Pruritus—Ritonavir—acquired immunodeficiency syndrome	0.000141	0.000528	CcSEcCtD
Trametinib—MAP2K2—MyD88 dependent cascade initiated on endosome—IL6—acquired immunodeficiency syndrome	0.000139	0.00187	CbGpPWpGaD
Trametinib—MAP2K2—IRS-related events—IL6—acquired immunodeficiency syndrome	0.000139	0.00187	CbGpPWpGaD
Trametinib—MAP2K2—IRS-related events triggered by IGF1R—IL6—acquired immunodeficiency syndrome	0.000137	0.00185	CbGpPWpGaD
Trametinib—Asthenia—Saquinavir—acquired immunodeficiency syndrome	0.000137	0.000515	CcSEcCtD
Trametinib—Vomiting—Delavirdine—acquired immunodeficiency syndrome	0.000137	0.000513	CcSEcCtD
Trametinib—MAP2K2—TCR Signaling Pathway—IL6—acquired immunodeficiency syndrome	0.000136	0.00183	CbGpPWpGaD
Trametinib—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	0.000136	0.000511	CcSEcCtD
Trametinib—MAP2K1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000136	0.00183	CbGpPWpGaD
Trametinib—Rash—Delavirdine—acquired immunodeficiency syndrome	0.000136	0.000509	CcSEcCtD
Trametinib—MAP2K2—Disease—CCNT1—acquired immunodeficiency syndrome	0.000136	0.00182	CbGpPWpGaD
Trametinib—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	0.000135	0.000508	CcSEcCtD
Trametinib—Pruritus—Saquinavir—acquired immunodeficiency syndrome	0.000135	0.000508	CcSEcCtD
Trametinib—Headache—Delavirdine—acquired immunodeficiency syndrome	0.000135	0.000506	CcSEcCtD
Trametinib—MAP2K2—Insulin receptor signalling cascade—IL6—acquired immunodeficiency syndrome	0.000134	0.0018	CbGpPWpGaD
Trametinib—MAP2K2—Toll Like Receptor 9 (TLR9) Cascade—IL6—acquired immunodeficiency syndrome	0.000134	0.0018	CbGpPWpGaD
Trametinib—MAP2K2—IGF1R signaling cascade—IL6—acquired immunodeficiency syndrome	0.000134	0.0018	CbGpPWpGaD
Trametinib—Nausea—Efavirenz—acquired immunodeficiency syndrome	0.000133	0.000501	CcSEcCtD
Trametinib—MAP2K1—IRS-mediated signalling—IL6—acquired immunodeficiency syndrome	0.000133	0.0018	CbGpPWpGaD
Trametinib—MAP2K1—MyD88 cascade initiated on plasma membrane—IL6—acquired immunodeficiency syndrome	0.000133	0.0018	CbGpPWpGaD
Trametinib—MAP2K1—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—IL6—acquired immunodeficiency syndrome	0.000132	0.00178	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—CCR2—acquired immunodeficiency syndrome	0.000132	0.00177	CbGpPWpGaD
Trametinib—MAP2K2—MyD88:Mal cascade initiated on plasma membrane—IL6—acquired immunodeficiency syndrome	0.000132	0.00177	CbGpPWpGaD
Trametinib—Dizziness—Ritonavir—acquired immunodeficiency syndrome	0.000131	0.000494	CcSEcCtD
Trametinib—Asthenia—Lamivudine—acquired immunodeficiency syndrome	0.000131	0.000492	CcSEcCtD
Trametinib—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	0.000131	0.000491	CcSEcCtD
Trametinib—MAP2K1—IRS-related events—IL6—acquired immunodeficiency syndrome	0.00013	0.00175	CbGpPWpGaD
Trametinib—MAP2K1—MyD88 dependent cascade initiated on endosome—IL6—acquired immunodeficiency syndrome	0.00013	0.00175	CbGpPWpGaD
Trametinib—Pruritus—Lamivudine—acquired immunodeficiency syndrome	0.000129	0.000485	CcSEcCtD
Trametinib—MAP2K1—IRS-related events triggered by IGF1R—IL6—acquired immunodeficiency syndrome	0.000129	0.00173	CbGpPWpGaD
Trametinib—Nausea—Delavirdine—acquired immunodeficiency syndrome	0.000128	0.000479	CcSEcCtD
Trametinib—MAP2K1—TCR Signaling Pathway—IL6—acquired immunodeficiency syndrome	0.000127	0.00172	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—ACTG1—acquired immunodeficiency syndrome	0.000127	0.00171	CbGpPWpGaD
Trametinib—MAP2K1—Disease—CCNT1—acquired immunodeficiency syndrome	0.000127	0.00171	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—IFNA1—acquired immunodeficiency syndrome	0.000127	0.00171	CbGpPWpGaD
Trametinib—Dizziness—Saquinavir—acquired immunodeficiency syndrome	0.000127	0.000475	CcSEcCtD
Trametinib—Vomiting—Ritonavir—acquired immunodeficiency syndrome	0.000126	0.000475	CcSEcCtD
Trametinib—MAP2K2—MyD88-independent cascade—IL6—acquired immunodeficiency syndrome	0.000126	0.0017	CbGpPWpGaD
Trametinib—Rash—Ritonavir—acquired immunodeficiency syndrome	0.000125	0.000471	CcSEcCtD
Trametinib—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	0.000125	0.00047	CcSEcCtD
Trametinib—MAP2K1—IGF1R signaling cascade—IL6—acquired immunodeficiency syndrome	0.000125	0.00169	CbGpPWpGaD
Trametinib—MAP2K1—Toll Like Receptor 9 (TLR9) Cascade—IL6—acquired immunodeficiency syndrome	0.000125	0.00169	CbGpPWpGaD
Trametinib—MAP2K1—Insulin receptor signalling cascade—IL6—acquired immunodeficiency syndrome	0.000125	0.00169	CbGpPWpGaD
Trametinib—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	0.000125	0.000469	CcSEcCtD
Trametinib—Headache—Ritonavir—acquired immunodeficiency syndrome	0.000125	0.000468	CcSEcCtD
Trametinib—MAP2K2—Toll-like Receptor Signaling Pathway—IL6—acquired immunodeficiency syndrome	0.000123	0.00166	CbGpPWpGaD
Trametinib—MAP2K1—MyD88:Mal cascade initiated on plasma membrane—IL6—acquired immunodeficiency syndrome	0.000123	0.00166	CbGpPWpGaD
Trametinib—Vomiting—Saquinavir—acquired immunodeficiency syndrome	0.000122	0.000457	CcSEcCtD
Trametinib—Dizziness—Lamivudine—acquired immunodeficiency syndrome	0.000121	0.000453	CcSEcCtD
Trametinib—Rash—Saquinavir—acquired immunodeficiency syndrome	0.000121	0.000453	CcSEcCtD
Trametinib—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	0.000121	0.000452	CcSEcCtD
Trametinib—Headache—Saquinavir—acquired immunodeficiency syndrome	0.00012	0.00045	CcSEcCtD
Trametinib—MAP2K2—Regulation of toll-like receptor signaling pathway—TNF—acquired immunodeficiency syndrome	0.000119	0.00161	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—ACTG1—acquired immunodeficiency syndrome	0.000119	0.0016	CbGpPWpGaD
Trametinib—MAP2K2—VEGFA-VEGFR2 Pathway—IL6—acquired immunodeficiency syndrome	0.000119	0.0016	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—IFNA1—acquired immunodeficiency syndrome	0.000119	0.0016	CbGpPWpGaD
Trametinib—MAP2K1—MyD88-independent cascade—IL6—acquired immunodeficiency syndrome	0.000118	0.00159	CbGpPWpGaD
Trametinib—Nausea—Ritonavir—acquired immunodeficiency syndrome	0.000118	0.000443	CcSEcCtD
Trametinib—MAP2K2—Signaling by Interleukins—IL6—acquired immunodeficiency syndrome	0.000118	0.00159	CbGpPWpGaD
Trametinib—Vomiting—Lamivudine—acquired immunodeficiency syndrome	0.000116	0.000436	CcSEcCtD
Trametinib—MAP2K1—Toll-like Receptor Signaling Pathway—IL6—acquired immunodeficiency syndrome	0.000115	0.00155	CbGpPWpGaD
Trametinib—Rash—Lamivudine—acquired immunodeficiency syndrome	0.000115	0.000432	CcSEcCtD
Trametinib—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	0.000115	0.000432	CcSEcCtD
Trametinib—Headache—Lamivudine—acquired immunodeficiency syndrome	0.000114	0.000429	CcSEcCtD
Trametinib—Nausea—Saquinavir—acquired immunodeficiency syndrome	0.000114	0.000427	CcSEcCtD
Trametinib—MAP2K2—Activated TLR4 signalling—IL6—acquired immunodeficiency syndrome	0.000114	0.00153	CbGpPWpGaD
Trametinib—MAP2K1—Senescence and Autophagy in Cancer—IL6—acquired immunodeficiency syndrome	0.000113	0.00152	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by VEGF—IL6—acquired immunodeficiency syndrome	0.000112	0.00151	CbGpPWpGaD
Trametinib—MAP2K1—Regulation of toll-like receptor signaling pathway—TNF—acquired immunodeficiency syndrome	0.000112	0.0015	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by Insulin receptor—IL6—acquired immunodeficiency syndrome	0.000111	0.0015	CbGpPWpGaD
Trametinib—MAP2K1—VEGFA-VEGFR2 Pathway—IL6—acquired immunodeficiency syndrome	0.000111	0.00149	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by Interleukins—IL6—acquired immunodeficiency syndrome	0.00011	0.00148	CbGpPWpGaD
Trametinib—Nausea—Lamivudine—acquired immunodeficiency syndrome	0.000108	0.000407	CcSEcCtD
Trametinib—MAP2K2—Toll Like Receptor 4 (TLR4) Cascade—IL6—acquired immunodeficiency syndrome	0.000107	0.00144	CbGpPWpGaD
Trametinib—MAP2K1—Activated TLR4 signalling—IL6—acquired immunodeficiency syndrome	0.000106	0.00143	CbGpPWpGaD
Trametinib—MAP2K2—Cytokine Signaling in Immune system—IFNG—acquired immunodeficiency syndrome	0.000105	0.00142	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by VEGF—IL6—acquired immunodeficiency syndrome	0.000105	0.00141	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—MBL2—acquired immunodeficiency syndrome	0.000105	0.00141	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by Insulin receptor—IL6—acquired immunodeficiency syndrome	0.000104	0.0014	CbGpPWpGaD
Trametinib—MAP2K2—MAPK Signaling Pathway—TNF—acquired immunodeficiency syndrome	0.000102	0.00138	CbGpPWpGaD
Trametinib—MAP2K1—Toll Like Receptor 4 (TLR4) Cascade—IL6—acquired immunodeficiency syndrome	9.99e-05	0.00135	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	9.92e-05	0.00134	CbGpPWpGaD
Trametinib—MAP2K1—Cytokine Signaling in Immune system—IFNG—acquired immunodeficiency syndrome	9.84e-05	0.00133	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—MBL2—acquired immunodeficiency syndrome	9.78e-05	0.00132	CbGpPWpGaD
Trametinib—MAP2K2—Regulation of toll-like receptor signaling pathway—IL6—acquired immunodeficiency syndrome	9.62e-05	0.0013	CbGpPWpGaD
Trametinib—MAP2K1—MAPK Signaling Pathway—TNF—acquired immunodeficiency syndrome	9.59e-05	0.00129	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—HLA-B—acquired immunodeficiency syndrome	9.54e-05	0.00128	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by SCF-KIT—IL6—acquired immunodeficiency syndrome	9.51e-05	0.00128	CbGpPWpGaD
Trametinib—MAP2K2—Toll-Like Receptors Cascades—IL6—acquired immunodeficiency syndrome	9.51e-05	0.00128	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	9.49e-05	0.00128	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	9.49e-05	0.00128	CbGpPWpGaD
Trametinib—MAP2K2—Cytokine Signaling in Immune system—IL2—acquired immunodeficiency syndrome	9.35e-05	0.00126	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	9.28e-05	0.00125	CbGpPWpGaD
Trametinib—MAP2K2—Downstream signaling of activated FGFR—IL6—acquired immunodeficiency syndrome	9.1e-05	0.00123	CbGpPWpGaD
Trametinib—MAP2K1—Regulation of toll-like receptor signaling pathway—IL6—acquired immunodeficiency syndrome	9e-05	0.00121	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	8.97e-05	0.00121	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by ERBB4—IL6—acquired immunodeficiency syndrome	8.96e-05	0.00121	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—HLA-B—acquired immunodeficiency syndrome	8.93e-05	0.0012	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by SCF-KIT—IL6—acquired immunodeficiency syndrome	8.9e-05	0.0012	CbGpPWpGaD
Trametinib—MAP2K1—Toll-Like Receptors Cascades—IL6—acquired immunodeficiency syndrome	8.9e-05	0.0012	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	8.88e-05	0.0012	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	8.88e-05	0.0012	CbGpPWpGaD
Trametinib—MAP2K1—Cytokine Signaling in Immune system—IL2—acquired immunodeficiency syndrome	8.75e-05	0.00118	CbGpPWpGaD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	8.65e-05	0.00116	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	8.58e-05	0.00116	CbGpPWpGaD
Trametinib—MAP2K2—Downstream signal transduction—IL6—acquired immunodeficiency syndrome	8.55e-05	0.00115	CbGpPWpGaD
Trametinib—MAP2K1—Downstream signaling of activated FGFR—IL6—acquired immunodeficiency syndrome	8.52e-05	0.00115	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by FGFR—IL6—acquired immunodeficiency syndrome	8.51e-05	0.00115	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by ERBB2—IL6—acquired immunodeficiency syndrome	8.47e-05	0.00114	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	8.44e-05	0.00114	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	8.44e-05	0.00114	CbGpPWpGaD
Trametinib—MAP2K2—DAP12 signaling—IL6—acquired immunodeficiency syndrome	8.43e-05	0.00113	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	8.4e-05	0.00113	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by ERBB4—IL6—acquired immunodeficiency syndrome	8.38e-05	0.00113	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—CCR2—acquired immunodeficiency syndrome	8.2e-05	0.0011	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	8.03e-05	0.00108	CbGpPWpGaD
Trametinib—MAP2K1—Downstream signal transduction—IL6—acquired immunodeficiency syndrome	8e-05	0.00108	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by FGFR—IL6—acquired immunodeficiency syndrome	7.96e-05	0.00107	CbGpPWpGaD
Trametinib—MAP2K2—Fc epsilon receptor (FCERI) signaling—IL6—acquired immunodeficiency syndrome	7.93e-05	0.00107	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by FGFR in disease—IL6—acquired immunodeficiency syndrome	7.93e-05	0.00107	CbGpPWpGaD
Trametinib—MAP2K2—DAP12 interactions—IL6—acquired immunodeficiency syndrome	7.93e-05	0.00107	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by ERBB2—IL6—acquired immunodeficiency syndrome	7.92e-05	0.00107	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	7.89e-05	0.00106	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	7.89e-05	0.00106	CbGpPWpGaD
Trametinib—MAP2K1—DAP12 signaling—IL6—acquired immunodeficiency syndrome	7.89e-05	0.00106	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—TAT—acquired immunodeficiency syndrome	7.86e-05	0.00106	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by EGFR—IL6—acquired immunodeficiency syndrome	7.86e-05	0.00106	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by EGFR in Cancer—IL6—acquired immunodeficiency syndrome	7.79e-05	0.00105	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by PDGF—IL6—acquired immunodeficiency syndrome	7.76e-05	0.00104	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CCR2—acquired immunodeficiency syndrome	7.67e-05	0.00103	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by FGFR in disease—IL6—acquired immunodeficiency syndrome	7.42e-05	0.000999	CbGpPWpGaD
Trametinib—MAP2K1—DAP12 interactions—IL6—acquired immunodeficiency syndrome	7.42e-05	0.000999	CbGpPWpGaD
Trametinib—MAP2K1—Fc epsilon receptor (FCERI) signaling—IL6—acquired immunodeficiency syndrome	7.42e-05	0.000999	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—IFNA1—acquired immunodeficiency syndrome	7.38e-05	0.000994	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR—IL6—acquired immunodeficiency syndrome	7.35e-05	0.00099	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR in Cancer—IL6—acquired immunodeficiency syndrome	7.29e-05	0.000981	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by PDGF—IL6—acquired immunodeficiency syndrome	7.26e-05	0.000977	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—CD79A—acquired immunodeficiency syndrome	7.17e-05	0.000965	CbGpPWpGaD
Trametinib—MAP2K2—Disease—CXCR4—acquired immunodeficiency syndrome	7.12e-05	0.000958	CbGpPWpGaD
Trametinib—MAP2K2—NGF signalling via TRKA from the plasma membrane—IL6—acquired immunodeficiency syndrome	7.02e-05	0.000946	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—IFNA1—acquired immunodeficiency syndrome	6.91e-05	0.00093	CbGpPWpGaD
Trametinib—MAP2K2—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	6.79e-05	0.000914	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CD79A—acquired immunodeficiency syndrome	6.71e-05	0.000903	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—AGPS—acquired immunodeficiency syndrome	6.68e-05	0.0009	CbGpPWpGaD
Trametinib—MAP2K1—Disease—CXCR4—acquired immunodeficiency syndrome	6.66e-05	0.000897	CbGpPWpGaD
Trametinib—MAP2K1—NGF signalling via TRKA from the plasma membrane—IL6—acquired immunodeficiency syndrome	6.57e-05	0.000885	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	6.42e-05	0.000864	CbGpPWpGaD
Trametinib—MAP2K1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	6.35e-05	0.000855	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	6.32e-05	0.000851	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	6.01e-05	0.000809	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	5.92e-05	0.000797	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	5.86e-05	0.000789	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—CD40LG—acquired immunodeficiency syndrome	5.84e-05	0.000787	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	5.78e-05	0.000779	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—CSF2—acquired immunodeficiency syndrome	5.78e-05	0.000778	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—CD8A—acquired immunodeficiency syndrome	5.78e-05	0.000778	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—CD4—acquired immunodeficiency syndrome	5.7e-05	0.000767	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—HLA-B—acquired immunodeficiency syndrome	5.56e-05	0.000748	CbGpPWpGaD
Trametinib—MAP2K2—Cytokine Signaling in Immune system—IL6—acquired immunodeficiency syndrome	5.49e-05	0.00074	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	5.48e-05	0.000739	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CD40LG—acquired immunodeficiency syndrome	5.47e-05	0.000736	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	5.41e-05	0.000729	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CD8A—acquired immunodeficiency syndrome	5.41e-05	0.000728	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CSF2—acquired immunodeficiency syndrome	5.41e-05	0.000728	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by NGF—IL6—acquired immunodeficiency syndrome	5.4e-05	0.000727	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—CD4—acquired immunodeficiency syndrome	5.33e-05	0.000718	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	5.3e-05	0.000714	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—HLA-B—acquired immunodeficiency syndrome	5.2e-05	0.0007	CbGpPWpGaD
Trametinib—MAP2K1—Cytokine Signaling in Immune system—IL6—acquired immunodeficiency syndrome	5.14e-05	0.000692	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—IL6—acquired immunodeficiency syndrome	5.05e-05	0.000681	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	4.98e-05	0.000671	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	4.98e-05	0.000671	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	4.96e-05	0.000668	CbGpPWpGaD
Trametinib—MAP2K2—Axon guidance—IL6—acquired immunodeficiency syndrome	4.89e-05	0.000658	CbGpPWpGaD
Trametinib—MAP2K2—Disease—CCR5—acquired immunodeficiency syndrome	4.88e-05	0.000657	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	4.66e-05	0.000628	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	4.66e-05	0.000628	CbGpPWpGaD
Trametinib—MAP2K1—Axon guidance—IL6—acquired immunodeficiency syndrome	4.57e-05	0.000616	CbGpPWpGaD
Trametinib—MAP2K1—Disease—CCR5—acquired immunodeficiency syndrome	4.56e-05	0.000615	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—TNF—acquired immunodeficiency syndrome	4.32e-05	0.000582	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—TAT—acquired immunodeficiency syndrome	4.22e-05	0.000568	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—TNF—acquired immunodeficiency syndrome	4.04e-05	0.000545	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.79e-05	0.000511	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.74e-05	0.000503	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—AGPS—acquired immunodeficiency syndrome	3.59e-05	0.000483	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.55e-05	0.000478	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.49e-05	0.000471	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—IL6—acquired immunodeficiency syndrome	3.49e-05	0.00047	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—IFNG—acquired immunodeficiency syndrome	3.44e-05	0.000463	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.42e-05	0.00046	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	3.34e-05	0.00045	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—CD4—acquired immunodeficiency syndrome	3.32e-05	0.000447	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—IL6—acquired immunodeficiency syndrome	3.26e-05	0.00044	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—IFNG—acquired immunodeficiency syndrome	3.21e-05	0.000433	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.2e-05	0.00043	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	3.13e-05	0.000421	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CD4—acquired immunodeficiency syndrome	3.1e-05	0.000418	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—IL6—acquired immunodeficiency syndrome	3.08e-05	0.000415	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	3.08e-05	0.000414	CbGpPWpGaD
Trametinib—MAP2K2—Disease—CD4—acquired immunodeficiency syndrome	3.06e-05	0.000413	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—IL2—acquired immunodeficiency syndrome	3.05e-05	0.000411	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—IL6—acquired immunodeficiency syndrome	2.88e-05	0.000388	CbGpPWpGaD
Trametinib—MAP2K1—Disease—CD4—acquired immunodeficiency syndrome	2.87e-05	0.000386	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—IL2—acquired immunodeficiency syndrome	2.86e-05	0.000385	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.97e-05	0.000266	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.96e-05	0.000264	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.85e-05	0.000249	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.84e-05	0.000247	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—IL6—acquired immunodeficiency syndrome	1.79e-05	0.000242	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—IL6—acquired immunodeficiency syndrome	1.68e-05	0.000226	CbGpPWpGaD
Trametinib—MAP2K2—Disease—IL6—acquired immunodeficiency syndrome	1.66e-05	0.000223	CbGpPWpGaD
Trametinib—MAP2K1—Disease—IL6—acquired immunodeficiency syndrome	1.55e-05	0.000209	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—ALB—acquired immunodeficiency syndrome	1.37e-05	0.000185	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.16e-05	0.000156	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.09e-05	0.000146	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ALB—acquired immunodeficiency syndrome	7.36e-06	9.91e-05	CbGpPWpGaD
